SLCI contributes to defects in oocyte quality, leading to ovulatory infertility, and accelerating the decline in ovarian reserve (35). Increased inflammatory response has been observed in the ovarian tissues of both PCOS patients and PCOS-like rodent models (15). Histological analysis comparing ovarian samples from of 53 PCOS patients and 48 healthy controls revealed a higher infiltration of macrophages and lymphocytes in PCOS patients. These cells secrete excessive amounts of pro-inflammatory cytokines such as TNF-α and IL-6 (9). Furthermore, inflammatory mediators such as IL-18, IL-18-binding protein (IL-18BP), pentraxin3 (PTX3), IL-1β, chemerin, hs-CRP, IFN-γ, and TNF-α were elevated in the FF from PCOS patients undergoing in vitro fertilization and embryo transfer (IVF-ET) treatment, reflecting the local function and pathological state within the PCOS ovaries (9, 36, 37). Macrophages and lymphocytes infiltration have also been detected in PCOS-like mice (38). PCOS-like rodent models exhibited increased levels of TNF-α, IFN-γ, NLRP3 and caspase-1within the ovaries (38, 39). These immune perturbations contribute to reduced fertility and metabolic comorbidities in PCOS-like models and PCOS patients. However, PCOS-like models may not fully replicate the complexity of PCOS in humans, particularly in terms of inflammatory markers and their expression levels. In PCOS patients, inflammation is influenced by factors such as obesity and IR which may not be identically represented in animal models of PCOS.

Pro-inflammatory TNF-α, primarily secreted by macrophages, was significantly increased in the ovaries and FF of PCOS patients (40, 41). TNF-α and its receptor TNFRI (TNF-a receptor 1) are expressed in mammalian oocytes and surrounding granulosa cells (GCs), indicating a direct impact of TNF-α on cells involved in reproductive function (42–44). In vitro experiments demonstrated that TNF-α can directly induce apoptosis of primary rat GCs after 24h of incubation in serum-free medium 24 (45). Furthermore, in vivo treatment with TNF‐α inhibits steroidogenesis of the thecal cells and GCs, leading to regression of the corpus luteal (21).

Another pro-inflammatory cytokine IL-6, which is produced by mononuclear (MNC) cells and adipose tissue cells. The levels of IL‐6 in the peripheral blood, ovaries, and FF in PCOS patients were higher than those in healthy control women (15, 46). IL-6 may serve as an early low-grade chronic inflammatory marker in PCOS patients with IRS-2 polymorphism (47). Higher IL-6 levels in the peripheral blood of both lean and obese women with PCOS were significantly associated with homeostasis model assessment of insulin resistance (HOMA2-IR) ratio and total testosterone ratios (48). Increased IL-6 levels in the ovary can reduce the conversion of androstenedione to estradiol by inhibiting the aromatase activity of GCs, leading to excessive androgen production (19, 49).

Inflammatory cytokines IL-1β and IL-18 present in the ovarian tissue and FF in PCOS patients alter the follicular microenvironment by binding to receptors like IL-1R and TLR4 on the GCs, activating NF-κB, which subsequently translocates into the nucleus (50). Activated NF-κB promotes gene expression of key components of the NLRP3 inflammasome, such as NLRP3, ASC and caspase-1, resulting in the death of GCs and inhibition of oocyte maturation, eventually disrupting ovarian function (50).

These results suggested that the increased pro-inflammatory profile in the ovary and FF mediates apoptosis of GCs, leading to excessive follicle atresia. This stimulates the production of excessive testosterone by thecal cells, disrupting the hypothalamic-pituitary-ovarian (HPO) axis, ultimately affecting dominant follicle generation, follicular dysfunction, and ovarian interstitial cell fibrosis (51, 52).

Successful pregnancy, encompassing embryo adhesion, implantation, growth, invasion of trophocytes, and formation and functional maintenance of the placenta, requires precise regulation of immune cells and inflammatory factors at the maternal-fetal interface to establish immune tolerance (53). This immune and inflammatory regulation in the endometrial tissue, also known as endometrial receptivity (ER), refers to the compatible state between the embryo and maternal uterus (54, 55). Reduced ER contributes significantly to early pregnancy loss, often resulting from dysregulation of immune and inflammatory responses in the endometrial tissue observed in women with autoimmune diseases (AID) or antiphospholipid syndrome (APS). Notably, the prevalence of recurrent miscarriages during early pregnancy due to an abnormal ER is higher in PCOS patients (56).

Immunohistochemical analysis of endometrial tissues from PCOS patients revealed an increase in the presence of endometrial inflammatory cells, including macrophages, iDCs, mature dendritic cells (mDCs), and CD8⁺ T cells (33), indicating increased chronic inflammation in the endometrial tissues. Additionally, PCOS endometrial stromal fibroblasts produce higher levels of IL-6, IL-8, MCP-1, and granulocyte-macrophage colony-stimulating factor (GM-CSF), which facilitate the maturation of endometrial DCs and macrophages, subsequently leading to progesterone resistance in the endometrium and impairing endometrial decidualization (57).

The NLRP3 inflammasome, which plays a crucial role in the processing of pro-IL-1β and pro-IL-18 into their mature forms through caspase-1, has been significantly increased in the endometrium of women with recurrent miscarriage (58), suggesting a potential dysregulation of ER mediated through inflammasome function. Therefore, NLRP3 may serve as a novel biomarker of ER dysfunction. As expected, increased expression of NLRP3 in the endometrial tissue has been implicated in the pathogenesis of higher miscarriage rates in PCOS patients (18, 59). In contrast, stanniocalcin-1 (STC-1), a glycoprotein, known for its ability to mitigate inflammatory stress is reduced in the endometrium of PCOS patients (60). This diminished expression of STC-1 may contribute to a weakened protective response to inflammatory stress (61). These findings suggested that the decrease in ER observed in PCOS is due to an imbalance between pro-inflammatory and anti-inflammatory cells and factors.

In addition to decreased ER, which contributes to adverse pregnancy outcomes, the chronic inflammation may also be associated with an increased long-term risk of endometrial carcinogenesis in PCOS patients. Simultaneously, the expression of both inflammation-related genes (CCL-2, IL-6, TNF-α, induced protein 6 [TNFAIP6] and pro-oncogenic genes (cell adhesion molecule with homology to L1CAM [CHL1]) is upregulated in the endometrium of PCOS patients than in controls (62). These findings highlight the importance of understanding and addressing the immunological and inflammatory aspects of PCOS to improve pregnancy outcomes and reduce long-term health risks for patients.

Autoimmune thyroid disease (AITD) is a common autoimmune disorder. PCOS and AITD share several clinical symptoms, including menstrual irregularities, infertility, obesity, IR, and dyslipidemia (63, 64).Therefore, screening for thyroid function and thyroid-specific autoantibodies is often recommended in the clinical diagnosis of PCOS. Furthermore, PCOS and AITD exhibit a strong clinical association. The prevalence of AITD in PCOS patients was significantly higher than that in the non-PCOS patients (65–68). Additionally, levels of thyroid-related autoantibodies, such as anti-TSH, anti-TPO, and anti-Tg, as well as T- and B-cell infiltration into the thyroid gland were higher in PCOS patients than controls (69–71). The elevated androgen levels in PCOS patients may contribute to AITD. Excessive androgens enhance the activity of T suppressor cells or promote Th1 responses, and Th1-mediated autoimmunity, resulting in thyroid cytolysis and hypothyroidism (68). Furthermore, PCOS patients exhibit compensatory increases in estrogen levels and inadequate progesterone levels. Estrogen may upregulate IL-6 expression in T cells, whereas inadequate of progesterone suppression potentially results in immune system overactivation (72). These findings indicates that the disruption of steroid hormones in PCOS patients contributes to inflammation dysregulation in the thyroid gland, leading to thyroid dysfunction. In summary, the clinical overlap between PCOS and AITD, along with the evidence of immune system dysregulation and thyroid dysfunction in PCOS patients, underscores the importance of considering thyroid health in the management of PCOS.

Pancreatic β-cell dysfunction is prevalent in PCOS patients, which significantly contributes to their abnormal glucose tolerance and the long-term risk of developing type II diabetes mellitus (T2DM) (73, 74). Malin et al. reported a direct relationship between β-cell dysfunction in PCOS patients and the MNC-derived NF-κB activation as well as an inverse correlation with IκB expression, indicating impaired inflammation regulation in the pancreas of PCOS patients (75). Conversely, nanocurcumin, a potential anti-inflammatory agent, significantly reduced oxidative markers and TNF-α levels in the pancreas, alleviated IR, restored islets integrity in PCOS models (75–77). Additionally, medications such as saxagliptin and metformin have demonstrated effectiveness in regulating β-cell function by reducing inflammation in newly diagnosed T2DM patients with PCOS (74).These findings suggest that the crucial role of pancreatic inflammation and β-cell dysfunction in PCOS-related metabolic complications and highlight the need for targeted interventions that can improve β-cell function and reduce inflammation.

Adrenal immune damage has recently been identified in patients with PCOS, coinciding with the overproduction of adrenal androgens(AA) (78, 79). Dehydroepiandrosterone (DHEA) and its sulfated form, dehydroepiandrosterone sulfate (DHEA-S), are the predominant AA in PCOS patients. DHEA synthesized in the adrenal gland is converted into DHEA-S and released into the bloodstream. Circulating DHEA-S levels has been used as a maker of adrenocortical dysfunction in PCOS (79). DHEA plays a role in maintaining ovarian immune homeostasis by modulating the balance between Th1 and Th2 immune responses within the ovary through NF-κB regulation, which decreases IL-2 and IL-10 (80). DHEA-S exerts immunomodulatory effects, reducing the T cell population with a concurrent increase in NK and T cells. These findings suggest a potential association between AA and immunological response in PCOS.

However, a retrospective cohort study identified a previously unrecognized infertile PCOS-like phenotype characterized by elevated levels of anti-Müllerian hormone (AMH) and low total testosterone, DHEA-S, and cortisol. Notably, this phenotype is also associated with increased levels of thyroid autoimmunity markers, such as thyroid autoimmunity (TPO antibodies) and the inflammatory markers CRP and IL-6. Therefore, this hypo-androgenic PCOS phenotype (HH-PCOS) may be related to the autoimmune damage in the adrenal zona reticularis (81, 82). However, further research is needed to confirm chronic inflammation in the adrenal glands and its potential effects on endocrine function in PCOS patients. These findings revealed a complex interplay between AA overproduction and immune dysfunction with adrenal gland in PCOS, Additionally, they indicate that infertile PCOS-like phenotype may be an immunoinflammatory disorder associated. This underscores the importance of reducing the AA levels and inflammation to ameliorate HH-PCOS.

Inflammatory markers, including IL-1β, IL-6, and TNF-α, were significantly upregulated within the hypothalamus of PCOS-like rats, indicating the presence of chronic low-grade neuroinflammation (83, 84). Hypothalamic inflammation contributes to the occurrence and progression of numerous metabolic disorders in PCOS, including obesity, diabetes, hypertension, and dyslipidemia, by affecting food intake homeostasis, energy balance, insulin and leptin signaling, glucose metabolism and fatty acid oxidation in the liver (85). High-fat diet (HFD)-induced overactivation and/or excessive M1-type macrophages-microglia, which is characterized by a pro-inflammatory response in the central nervous system. This M1-polarized microglia induce an inflammatory response and release a large number of inflammatory factors, such as nitric oxide, IL-6, TNF-α, and reactive oxygen species (ROS), which are key drivers of hypothalamic inflammation (86–89). Furthermore, hypothalamic inflammation alters the pulsatile secretion pattern of gonadotropin-releasing hormone (GnRH), resulting in an increase in luteinizing hormone (LH)/follicle stimulating hormone (FSH) ratios and leading to irregular menstrual cycles and ovulatory disorders (90). These findings highlight the strong association between hypothalamic inflammation and the etiology and phenotype of PCOS, suggesting that targeting hypothalamic inflammation could be a potential therapeutic strategy (91).

The risk of CVDs is higher in PCOS patients (92–94). Vascular alterations, such as endothelial dysfunction, increased arterial stiffness, enhanced intima-media thickness, and arterial wall calcification, are prevalent even in young women with PCOS (94–96). Furthermore, vascular endothelial injury and endothelial cell dysfunction in PCOS patients are independent of age, body weight, and metabolic abnormalities, suggesting that PCOS may be an independent risk factor for CVDs and could lead to an earlier onset of CVDs despite the presence of metabolic disorders (97, 98).The current consensus is that chronic inflammation of the vascular endothelium and the resulting endothelial dysfunction are fundamental to the pathogenesis of CVDs (99, 100). Additionally, pro-inflammatory factors such as CRP, IL-6 and IL-18, which are closely associated with the incidence of CVDs, are also elevated in the plasma of women with PCOS patients (18).

The critical role of macrophages in the pathogenesis of CVDs in PCOS has been recently reported, with a substantial augmentation in the number of M1-macrophages in the hearts of PCOS model mice, predominantly derived from circulating monocytes (10). Furthermore, PCOS mice with atherosclerosis and myocardial infarction exhibited a pronounced infiltration of macrophages into the myocardium (10). The adverse cardiovascular effects of PCOS could be attributed to the over-activation of the norepinephrine-NF-κB pro-inflammatory signaling pathway, contributing to increased expression of a hematopoietic progenitor retention factor, vascular cell adhesion molecule 1(Vcam1), in splenic macrophages, subsequently resulting in increased circulating total monocytes and inflammatory monocytes. These findings indicate that the accumulation of macrophages in the heart contributes to endothelial dysfunction, emphasizing the need to address chronic inflammatory state in PCOS patients for effective management of their cardiovascular health (10).

The prevalence of NAFLD is higher in PCOS patients than in healthy women (34%–70% vs. 14%–34%) (101, 102). IR, obesity, HA, chronic inflammation, genetic factors and dyslipidemia are risk factors for NAFLD development in PCOS patients (103–105). Interestingly, HA in PCOS is an independent risk factor for NAFLD, as demonstrated in a recent systematic review and meta-analysis (101, 106). Bioinformatics data identified 52 differentially expressed genes (DEGs) shared between PCOS and NAFLD. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses suggested that these DEGs were mostly enriched in immunity- and inflammation-related pathways (107). NAFLD-like hepatic pathological changes such as steatosis, inflammatory cell infiltration, necrotic hepatocytes, and liver fibrosis, accompanied by increased expression of inflammatory cytokines (TNF-α, IL-1β), stress-related protein urocortin-1, antioxidant gene glutathione peroxidase-1 (Gpx1), and the NLRP3 inflammasome within the hepatic tissues, have been observed in several rodent models of PCOS (108–111). Over-production of these pro-inflammatory mediators in the liver of individuals with PCOS leads to the infiltration of various immune cells, including macrophages, T lymphocytes, dendritic cells, and neutrophils (11). These cells further release additional inflammatory cytokines that interact with adipokines, such as leptin, adiponectin, vaspin, visfatin, and chimerin. This exacerbates the imbalance between the pro-inflammatory and anti-inflammatory states within the liver, ultimately contributing to the development of the NAFLD in PCOS (12).

The association between PCOS and inflammatory diseases of the lung has not been extensively investigated. Recent studies on the association between PCOS and coronavirus-induced disease 19 (COVID-19) have provided valuable insights. COVID-19 is characterized by an excess of pulmonary inflammatory cells such as macrophages, neutrophils, and dendritic cells and elevated levels of inflammatory factors, including IL-2, IL-7, IL-10, G-CSF, IP-10, MCP-1, MIP1A, and TNF-α. Overproduction of these factors can ultimately lead to damage and death of alveolar epithelial cells, potentially leading to respiratory failure and death (112). PCOS patients are more susceptible to infection by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) and exhibit more severe clinical symptoms than those of control women without PCOS (113). PCOS patients exhibit higher infection rates (28%–50%) across all age groups, leading to increased hospitalization rates and morbidity and mortality rates than those of age-matched women without PCOS. HA may be a factor in the increased susceptibility to SARS-CoV-2 in PCOS in individuals with PCOS (114). In dihydrotestosterone (DHT)-induced PCOS-like female mice, DHT up-regulates ACE2 mRNA in the lung, cecum, heart and kidney, which synergizes with host transmembrane protease serine 2 (TMPRSS2) to facilitate SARS-CoV-2 viral entry into the host cells (115). These findings suggest that PCOS patients, particularly those with HA, are more susceptible to COVID-19, which leads to increased pulmonary inflammation and damage in the lung tissues, ultimately contributing to an increased mortality rate.

Approximately 5%-10% of reproductive-age women without PCOS worldwide experience depression and anxiety, and 40% of women with PCOS suffer from depression (1, 116). Psychiatric disorders, including generalized depressive disorder, are inflammatory conditions characterized by elevated levels of inflammatory markers (117–119). Inflammatory markers such as CRP, IL-1, IL-6 and TNF-α elevated both in patients with depression and PCOS (120, 121). Inflammatory factors may penetrate the blood-brain barrier (BBB) via cytokine-specific transport mechanisms, potentially involving the active transport of saturable transporter molecules (122, 123). Subsequently, increased inflammatory factors can disrupt the metabolism of brain monoamines such as neuronal 5-hydroxytryptamine (5HT) and dopamine (DA), which are hypothesized to contribute to the pathogenesis of depressive disorders (124–126). Nevertheless, experimental animal studies to elucidate the mechanisms by which inflammatory mediators induce depressive disorders in PCOS are lacking. The complex relationship between PCOS and psychiatric disorders, particularly depression and anxiety, underscores the need for further research to better understand and address these comorbidities.

The primary etiology and symptoms of PCOS are predominantly associated with the dysregulation of steroid hormones, particularly elevated levels of androgen and decreased progesterone levels linked to luteal phase deficiency. Both androgens and progesterone play crucial roles in the inflammation response. As a pro-inflammatory steroid hormone, HA induces SLCI in the ovaries by stimulating monocyte infiltration, enhancing ROS production, and activating the NF-κB pathway, which contributes to metabolic disorders in PCOS patients (141). Additionally, HA promotes the secretion of and pro-inflammatory factors, subsequently suppressing folliculogenesis and ovulation, resulting in a cascade of events including pyroptotic death of ovarian GCs, follicular dysfunction, and ovarian interstitial cell fibrosis (15, 142). Increased endometrial cytokine synthesis and inflammation in PCOS patients induced by excess androgens through TLR4/IRF-7/NF-κB signaling contributes to inflammation in PCOS patients (143). Higher serum total testosterone and free testosterone index (FTI) were also found to be linked to an elevated risk of NAFLD in women with PCOS, independent of obesity and IR (106, 144, 145). HA induces ovarian inflammation in PCOS mice by activating the NLRP3 inflammasome, resulting in follicular dysfunction, ovarian fibrosis, and pyroptotic death (146). In vitro studies have indicated that DHEA directly inhibits the proliferation and promotes apoptosis of human ovarian granulosa tumor cell line (KGN) cells by down-regulating IFN-γ expression via the activation of the PI3K/AKT signaling pathway (147). DHEA administration directly activates the MNC cells and increases heightened sensitivity to glucose intake. In lean, healthy women, oral androgens increase mRNA expression of androgen receptors (AR) and stimulate TNF-α release from MNC in response to glucose-induced inflammation (148, 149).

Progesterone, a critical anti-inflammatory steroid hormone, has recently been studied. Although the exact anti-inflammatory mechanism of progesterone remains unclear, current evidence suggests that its effects encompass both non-specific and specific immune regulation. The non-specific regulation is hypothesized to involve the inhibition of NF-κB activation, cyclooxygenase (COX) and prostaglandin synthesis. On the other hand, specific immune regulation is thought to include the modulation of T cell activation and cytokine production by immune cells (150). Notably, a study conducted on patients with COVID-19 demonstrated that progesterone exhibited therapeutic effects that are comparable to those of glucocorticoids in preventing severe illness and mortality associated with SARS-Cov2 infection (151–153). Furthermore, progesterone decreases the production of IL-1β, IL-6, TNF-α, and IL-12, as well as MCP-1/CCL2, suggesting it as a valuable adjunct to current SARS-CoV-2 treatment regimens (154). In PCOS patients, oligo/anovulation leads to reduced progesterone levels, which may result in inadequate inhibition of inflammation at the myometrium and maternal-fetal interface (155–158). This deficiency is associated with an increased risk of adverse pregnancy outcomes (159). Moreover, progesterone enhances the release of gonadotropin-releasing hormone (GnRH) and increases the sensitivity of the pituitary gland to GnRH, thereby triggering an LH surge. This results in the normalization of hyperandrogenemia and hyperinsulinemia levels, restore the physiological balance between androgens, estradiol, and progesterone within the menstrual cycle (160). Consequently, PCOS patients with progesterone deficiency may be at an increased risk of developing multi-system diseases owing to elevated systemic inflammation.

Estrogen plays a dual role in regulating the immune system in women. During pregnancy, elevated estrogen levels inhibit the production of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, MCP-1, iNOS, and MMPs. Concurrently, it reduces NK cell activity. Additionally, high concentrations of estradiol stimulate anti-inflammatory cytokines such as IL-4, IL-10, and TGF-β. This indicates that the sustained high levels of estrogen, in conjunction with progesterone, during gestation, play a synergistic role in suppressing the immune response and inflammation, which is crucial for the preservation of normal fetal development (161). In contrast, at the lower concentrations observed in non-pregnancy states, estrogen stimulates the production of inflammatory cytokines such as TNF-α, IFN-γ, and IL-1β, while also enhancing the activity of NK cells (161). Clinically, estrogen supplementation has shown anti-inflammatory and protective effects under certain conditions associated with chronic inflammation, such as osteoporosis, CVDs, and neurodegeneration during menopausal hormone replacement therapy (MHT) (162). Conversely, estrogen exerts pro-inflammatory effects in specific autoimmune diseases (AIDs), including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), highlighting estrogen as a risk factor for the increased incidence of various AIDs in women than in men (161, 163). PCOS patients may exhibit a lower average estrogen level owing to the absence of the fluctuations and peaks that typically occur during ovulation and the luteal phase in non-PCOS women with regular ovulation. Although estrogen levels can reach the pregnancy-like concentrations during ovulation in healthy individuals, the oligo/anovulation characteristic of PCOS leads to a deficiency in high estrogen levels, which may predispose individuals to excessive inflammation. Further investigations are necessary to clarify the potential role of estrogen in the regulation of chronic systemic inflammation associated with PCOS.

A healthy diet is the cornerstone of a healthy lifestyle and can significantly ameliorate the symptoms of intestinal dysbiosis, inflammatory status, and reproductive and metabolic abnormalities in PCOS. A clinical study reported that the very low-calorie ketogenic diet (VLCKD) improved ovarian function in obese women with PCOS. In this study, 25 obese patients with PCOS were enrolled to receive a VLCKD intervention for 12 weeks. Significant reductions in BMI, waist circumference (WC), and HOMA were observed. These results suggest that VLCKD may be an effective strategy for ameliorating metabolic and ovulation dysfunction in women with PCOS (223).

The Mediterranean diet (MD), known for its anti-inflammatory properties, has shown promise in managing PCOS. Barrea et al. conducted a case-controlled cross-sectional study that revealed that high adherence to the MD diet resulted in lower CRP levels, HoMA-IR, testosterone levels, and Ferriman-Gallwey scores. This preliminary evidence suggests that the MD diet reduces disease severity, IR, and hyperandrogenemia in PCOS (224).

Intermittent fasting has emerged as a viable approach for reducing weight and energy intake. The forms of intermittent fasting include three diets: alternate-day fasting (ADF), 5:2 diet, and time-restricted eating (TRE). A clinical study reported 15 anovulatory PCOS patients aged 18–31 years who completed 8-h time-restricted feeding for 6-weeks experienced substantial improvements. After TRE, body weight, BMI, HOMA-IR, and hs-CRP decreased, whereas SHBG and insulin-like growth factor 1(IGF-1) levels increased, and irregular menstrual cycles improved in 73.3% (11/15) of patients (225).

These results underscore the potential of a healthy diet in reducing weight and body fat and improving menstruation, hyperandrogenemia, IR, and chronic inflammation in PCOS patients.

Nutrients, mainly including vitamins (such as vitamin D), vitamin-like nutrients (such as α-lipoic acid), and minerals (such as magnesium), are essential components of a healthy diet. Nutrient supplementation can have a positive impact on PCOS patients (226). A randomized double-blind placebo-controlled clinical trial conducted by Bahmani et al. demonstrated that folic acid supplementation significantly reduced the plasma levels of Hcy, HOMA-B, hs-CRP, and MDA and significantly increased the plasma levels of TAC and GSH. These findings suggest that folic acid supplementation has a potential clinical role in improving metabolic conditions and reducing inflammation and oxidative stress in PCOS patients (227). In a randomized, double-blind, placebo-controlled trial involving patients with PCOS, 60 participants were randomly assigned to two groups (n = 30 in each group), one receiving a supplement of 1000 mg omega-3 and 400 IU of vitamin E, and the other receiving a placebo for a duration of 12 weeks. The study results indicated that the combined supplementation of omega-3 and vitamin E significantly reduced CIMT and serum hs-CRP levels (228). In a clinical study conducted by Stracquadanio et al., continuous administration of myo-inositol, gymnemic acid, and L-methylfolate for 6 months demonstrated substantial beneficial effects in PCOS patients, including improvement in menstrual cycle regularity and metabolic parameters, reduction in BMI and total testosterone, and increased insulin sensitivity (229). Hager et al. conducted a randomized controlled trial investigating the effects of a standardized micronutrient supplementation in PCOS patients. The supplement included omega-3 fatty acids, folic acid, selenium, vitamin E, catechin, glycyrrhizin, and coenzyme Q10, which was administered for 3 months. The study demonstrated that compared with the control group, the group receiving the micronutrient supplement experienced a significant decrease in the LH/FSH ratio, testosterone, and AMH levels (230). These findings indicated that nutrient supplementation may be beneficial for ameliorating some of the adverse health outcomes associated with PCOS. Specifically, nutritional supplements can potentially improve menstrual cycle regularity, IR, inflammation, and oxidative stress in PCOS patients.

Physical activity is recommended as a first-line approach for managing PCOS, particularly for overweight or obese women. The guidelines recommend a minimum of 150 min/week of moderate-intensity exercise, 75 min/week of vigorous-intensity exercise, or a combination of both (231). A meta-analysis by Moori et al. demonstrated that exercise training effectively lowered inflammatory markers, such as serum CRP levels (232). In a randomized clinical trial, high-intensity interval training (HIIT) elicited greater improvements in cardiometabolic and reproductive outcomes than moderate-intensity interventions in overweight women with PCOS. Patten et al. further found that HIIT considerably improved the oxygen-carrying capacity of blood than did moderate-intensity exercises. HIIT substantially increased SHBG levels and regularized menstrual cycles in PCOS patients (233). In summary, engaging in regular physical activity, particularly HIIT, is beneficial for women with PCOS, as it not only helps in managing weight but also has positive effects on inflammation, cardiometabolic health, and reproductive function. These findings emphasize the importance of incorporating exercise into the treatment plan for PCOS, highlighting its potential to improve the overall health and quality of life of affected individuals.

Metformin, a biguanide, improves insulin sensitivity, reduces androgen levels, and enhances oligo-amenorrhoea and subfertility in women with PCOS (234). Metformin increases gut Akkermansia abundance, reduces serum IFN-γ level released from T cells, and inhibits macrophage pyroptosis in ovaries in PCOS mice (234). Xue et al. revealed metformin alleviated PCOS by modulating gut microbiota, reducing plasma LPS levels, and decreasing the plasma and ovarian levels of inflammatory cytokines, including TNF-α, IL-6, and IL-17A, in PCOS patients (235).

Traditional Chinese Medicine (TCM) formulations and their active ingredients have been widely used to treat various gynecological diseases, including PCOS. Herbal medicines and active ingredients regulate gut microbiota composition and reduce systemic and ovarian inflammation in PCOS-like models (236–238). Wang et al. reported the TCM decoction Bu Shen Hua Zhuo formula (BSHZF) administration improved gut microbiota function in rats with letrozole-induced PCOS and inhibited the activation of the TLR4/NF-kB signaling pathway in PCOS-related ovarian tissue, decreasing the pro-inflammatory cytokines TNF-a, IL-6, and IL-8 (236). Zhu et al. reported Gui-zhi-Fu-ling Wan treatment reduced inflammatory markers such as hs-CRP, IL-6, and TNF-α and improved PCOS-IR by remodeling the relative abundance of multiple intestinal flora (237). Chang et al. reported that Shaoyao-Gancao Decoction (SGD), commonly used to treat multiple gynecological disorders such as dysmenorrhea, adenomyosis, and PCOS, modulated gut microbiota composition, and alleviated chronic low-grade inflammation by downregulating cytokines including IL-18, IL-1β, IL-6, and TNF-α in both serum and ovarian mRNA expression in PCOS rats (238). In summary, these studies underscore the therapeutic potential of TCM for treating PCOS by targeting gut microbiota and inflammatory pathways, which may offer a complementary approach to conventional treatments. Modulation of the gut microbiota using TCM formulations holds promise as a therapeutic strategy for PCOS.

In clinical practice, other pharmacological interventions for PCOS include combined oral contraceptives (COCs) and antiandrogens. COCs are commonly prescribed to PCOS patients with menstrual irregularities and clinical hyperandrogenism. COCs reduce free testosterone levels by increasing SHBG production in the liver, thereby alleviating hyperandrogenism (239). Anti-androgens such as finasteride, flutamide, spironolactone, or bicalutamide, along with lifestyle modifications, are more effective in improving hirsutism, SHBG, fasting insulin, and the fasting insulin:glucose ratio. Current evidence does not support the preferential use of anti-androgens over COCs for the treatment of hyperandrogenism in PCOS. However, antiandrogens are not preferred over COCs for hyperandrogenism unless COCs are contraindicated or ineffective (240). Moreover, low-dose spironolactone in PCOS rats reduces the oxidative stress markers (MDA) and inflammatory biomarkers such as NF-kB, TNF-α, and IL-6 (241).